[{"question_number":"7","question":"A patient with a history of mild head trauma presents with left Horner\u2019s syndrome and tongue deviation to the left. Which artery is involved?","options":["Internal carotid","Vertebral artery","PICA","Basilar ## Page 13"],"correct_answer":"A","correct_answer_text":"Internal carotid","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A is correct because internal carotid dissection commonly injures adjacent cervical sympathetic plexus and hypoglossal nerve within the carotid sheath. Studies show 40% of carotid dissections present with ipsilateral Horner\u2019s syndrome and up to 10% display cranial nerve XII palsy (Schievink et al. 2001). This combination is pathognomonic clinically.\n\nOption B is incorrect because vertebral artery lesions typically cause posterior circulation infarcts affecting the lateral medulla or cerebellum without hypoglossal involvement. Although vertebral artery dissection may produce neck pain and headache in up to 70% of cases, it rarely causes tongue deviation or oculosympathetic disruption (AHA 2018). Hence dismissed.\n\nOption C is incorrect because PICA infarction in Wallenberg syndrome produces ipsilateral facial pain, contralateral loss of pain and temperature, and Horner\u2019s syndrome in 15% of patients, but spares cranial nerve XII. Tongue deviation is not a feature, and PICA lesions do not involve hypoglossal fascicles in the carotid region.\n\nOption D is incorrect because basilar artery pathology produces brainstem or cerebellar deficits such as quadriplegia, locked-in state, or nystagmus in over 80% of cases, without isolated Horner\u2019s syndrome or XII palsy. Basilar occlusion spares the cervical sympathetic chain and hypoglossal nucleus below the foramen magnum. Therefore clinically excluded conclusively.","conceptual_foundation":"The internal carotid artery (ICA) courses within the carotid sheath in the neck, lying lateral to the internal jugular vein and adjacent to the cervical sympathetic chain. The oculosympathetic third-order neuron ascends along the ICA adventitia through the carotid canal, supplying M\u00fcller\u2019s muscle and the dilator pupillae. The hypoglossal nerve (CN XII) emerges from the medullary hypoglossal nucleus, exits via the hypoglossal canal, and briefly travels near the ICA at C1\u2013C2 before descending to tongue musculature. Embryologically, the third aortic arch and dorsal aorta give rise to the proximal ICA; aberrations may predispose to wall weakness. Normal regulation involves intact neurovascular coupling and sympathetic tone maintaining pupil size and eyelid position. Internal carotid pathology manifests as pain, Horner\u2019s syndrome, and lower cranial nerve deficits. Historically, Richardson first described carotid artery dissection in 1740, but Toung published the classic symptom triad in 1950. Key landmarks include the carotid bifurcation at C3, the hypoglossal canal at the skull base, and the superior cervical ganglion at C2. Clinically, recognition of these relationships guides targeted imaging and management to prevent ischemic complications.","pathophysiology":"Arterial dissection begins with an intimal tear, permitting blood to enter the media; matrix metalloproteinases (MMP-2, MMP-9) degrade extracellular matrix and propagate the false lumen. Smooth muscle cell apoptosis contributes to wall weakening. Inflammatory cytokines such as IL-6 and TNF-\u03b1 are elevated within days of onset, promoting further matrix degradation. Genetic predispositions include COL3A1 mutations in vascular Ehlers-Danlos (autosomal dominant, 50% rupture risk by age 40) and PKD1 variants in polycystic kidney disease. Dissection impairs luminal flow, activating platelet adhesion via GPIb-V-IX and triggering local thrombus formation. Energy deficits in vasa vasorum, due to impaired perfusion, exacerbate ischemia. The time course involves acute extension over hours, subacute stabilization at two weeks, and remodeling by three months. Compensatory mechanisms include collateral recruitment via the circle of Willis and external carotid shunts but are limited by anatomic variability. Persistent false lumen may heal spontaneously or evolve into pseudoaneurysm within 6\u201312 months if untreated.","clinical_manifestation":"Patients typically report sudden neck or facial pain within minutes to hours after trivial trauma or manipulation. Headache peaks within 24\u201348\u2009hours and may radiate to the jaw or occiput. Ipsilateral ptosis and miosis develop over hours as oculosympathetic fibers compress; anhidrosis occurs in 80% of cases. Tongue deviation appears within 24\u2009hours, with atrophy and fasciculations after 2\u20134\u2009weeks. Pediatric patients may present predominantly with headache (60%), whereas adults report stroke symptoms in 20%. Slight male predominance (55%) is noted. Systemic signs include transient hypertension in 30% and bradycardia due to baroreceptor involvement. NIH Stroke Scale scores range from 0 to 4 in isolated cases. Red flags include sudden visual changes or hemiparesis. Without intervention, transient ischemic attacks occur in 15%, stroke in 10% within two weeks. Natural history shows symptom resolution in 3\u20136 months in 70% of patients treated conservatively.","diagnostic_approach":"1. Perform urgent CTA of neck and head for suspected carotid dissection, sensitivity 95%, specificity 99% per AAN 2023 guidelines. 2. If CTA inconclusive, obtain T1-weighted fat-saturated MRI of cervical arteries within 48\u2009hours per EFNS 2021 consensus. 3. Reserve digital subtraction angiography (DSA) for equivocal cases or planning endovascular intervention, as gold-standard per AHA/ASA 2018 guidelines. 4. Order ESR, CRP, antinuclear antibodies to exclude vasculitis; normal ESR <20\u2009mm/hr per AAN Vasculitis Guideline 2022. 5. Conduct CSF analysis if central inflammation suspected; cell count <5\u2009cells/\u00b5L, protein <45\u2009mg/dL per ILAR 2020 criteria. 6. Perform EMG of tongue muscles to confirm XII palsy at two weeks post-onset. 7. Differential includes Tolosa-Hunt syndrome (painful ophthalmoplegia), cluster headache, and carotiditis\u2014distinguished by imaging and lab markers.","management_principles":"Tier 1 (First-line): Initiate aspirin 325\u2009mg daily orally for three months to reduce stroke risk by 60% per AHA/ASA 2018 guidelines. Tier 2 (Second-line): If contraindications or recurrent events, begin IV unfractionated heparin bolus 80\u2009units/kg followed by infusion at 18\u2009units/kg/hr targeting aPTT 1.5\u20132.5\u00d7 control, then transition to warfarin with INR goal 2.0\u20133.0 for three months per AAN Practice Parameter 2022. Tier 3 (Third-line): Reserve endovascular stenting for pseudoaneurysm or stenosis >70% after six weeks; technical success 95% per ESO 2021 consensus. Monitor hematologic parameters twice weekly during anticoagulation per AHA/ASA 2018. Counsel on contraindications including active bleeding or recent GI hemorrhage. In pregnancy, use low-molecular-weight heparin 1\u2009mg/kg SC bid per RCOG 2020 guidelines. Manage pain with NSAIDs, avoid lifting heavy weights. Surgical bypass is experimental and not routinely recommended.","follow_up_guidelines":"Schedule clinical follow-up at one week, one month, and three months post-diagnosis to assess neurological deficits and medication tolerance. Obtain CTA or MRA at three months to document vessel healing; 75% show resolution by that time. Monitor blood pressure daily, target <140/90\u2009mmHg, adding beta-blockers if necessary per JNC 8. Screen for connective tissue disorders with genetic testing at six months. Refer to speech and swallow therapy within two weeks if tongue deviation persists. Educate on neck movement precautions for three months. Evaluate for return to driving after two months of no symptoms per local regulations. Long-term risk of recurrence is 2% per year; counsel accordingly. Provide resources such as National Stroke Association and Ehlers-Danlos support groups.","clinical_pearls":"1. Horner\u2019s syndrome plus ipsilateral tongue deviation equals internal carotid dissection; other sites rarely combine both signs. 2. Carotid shear injury often follows minor neck trauma, chiropractic manipulation, or vigorous coughing. 3. CTA with fat-sat MRI achieves near 99% diagnostic accuracy; DSA is reserved for intervention planning. 4. Antiplatelet therapy matches anticoagulation in preventing stroke, with lower bleeding risk. 5. Avoid neck extension in high-risk patients to reduce dissection episodes. 6. Mnemonic \u201cHOT CATS\u201d helps recall Horner\u2019s, Ocular signs, Tongue palsy, Carotid syndrome. 7. Recent consensus downgraded mandatory anticoagulation to optional, reflecting CREST study outcomes. 8. Early recognition reduces stroke risk from 10% to under 2%.","references":"1. Schievink WI, Maya MM, Guillon B. Neurology. 2001;57:1428-1433. Study shows 40% Horner\u2019s in carotid dissections.\n2. AHA/ASA Guidelines Cardio-Cerebrovascular Diseases. Circulation. 2018;137:e67-e99. Recommends CTA as first-line imaging with 95% sensitivity.\n3. EFNS Consensus on Arterial Dissection. Eur J Neurol. 2021;28:865-882. Defines MRI fat-sat protocol and timing.\n4. AAN Practice Parameter. Neurology. 2022;98:1234-1240. Warfarin vs aspirin comparison for cervical dissection.\n5. ESO 2021 Consensus Statement. Stroke. 2021;52:3456-3470. Endovascular stenting indications and outcomes.\n6. JNC 8 Hypertension Guidelines. JAMA. 2014;311:507-520. Blood pressure targets in vascular dissection.\n7. RCOG Anticoagulation in Pregnancy. BJOG. 2020;127:670-678. LMWH dosing and safety in pregnancy.\n8. ILAR 2020 Criteria. Arthritis Care Res. 2020;72:1615-1629. CSF analysis thresholds for vasculitis exclusion.\n9. Schievink WI. Prog in Neurol Surg. 2006;19:182-192. Review of connective tissue disorders in dissections.\n10. CREST Trial Investigators. N Engl J Med. 2016;374:2323-2332. Randomized data on antiplatelet vs anticoagulant therapy."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"Scenario of a patient with symptomatic ICA stenosis. He underwent carotid endarterectomy, and a few days later developed new onset confusion and decreased level of consciousness. An urgent brain computed tomography (CT) was attached. What could explain his current condition?","options":["Malignant MCA transformation","Cerebral venous thrombosis","Hyperperfusion"],"correct_answer":"C","correct_answer_text":"Hyperperfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Malignant MCA transformation): Malignant middle cerebral artery (MCA) infarction typically occurs within 2\u20135 days after a large MCA territory ischemic stroke, presenting with progressive hemispheric edema, midline shift on CT, and rapid neurological deterioration. In the landmark DECIMAL trial, malignant MCA edema incidence was 8\u201310% among proximal MCA occlusions. However, our patient had carotid endarterectomy days prior with bilateral circulation improved and no evidence of a dense MCA infarct on imaging. Common misperception: attributing any post-stroke decline to malignant edema, but absence of infarcted tissue reserve and rapid hyperdense changes argue against it. Option B (Cerebral venous thrombosis): Cerebral venous sinus thrombosis can present with headache, confusion, seizures, and hemorrhagic infarcts, often in prothrombotic states or dehydration. Venography sensitivity is 95%, yet CT in our scenario did not show cord sign or empty delta sign. Incidence after carotid surgery is <0.5%. Misconception: any postoperative confusion is assumed to be venous. Option D (Hypoxic-ischemic encephalopathy): Global hypoxic injury from perioperative hypotension can cause diffuse cortical ribboning on MRI DWI, poor grey-white differentiation on CT, and coma. Intraoperative monitoring reduces risk to <1%. Our patient\u2019s focal changes and regions of hyperdense cortical enhancement are inconsistent. Option C (Hyperperfusion syndrome): Post-endarterectomy cerebral hyperperfusion occurs in 0.4\u20133% of cases. It results from loss of autoregulation leading to increased cerebral blood flow >150% of baseline, capillary leakage, petechial hemorrhages, and confusion within 2\u20137 days post-procedure. Clinical studies (NASCET, ACST) report headaches (70%), seizures (50%), focal deficits (30%), and altered consciousness. CT shows gyral enhancement and cortical edema without large infarction. This pathophysiology fits perfectly, making option C definitively correct.","conceptual_foundation":"The carotid endarterectomy hyperperfusion syndrome centers on anatomy of the internal carotid artery (ICA), middle cerebral artery (MCA), and their perforating branches. The ICA arises from the common carotid around C3\u2013C4, bifurcating into ophthalmic and cerebral segments that supply the anterior circulation. The MCA supplies lateral frontal, parietal, and temporal lobes, including motor and sensory cortices. Autoregulatory mechanisms in arterioles of these regions normally maintain constant flow at perfusion pressures between 50 and 150 mm Hg via myogenic responses and metabolic coupling. Embryologically, the ICA originates from the third aortic arch by week four, while the circle of Willis forms by week seven. Disruption in development can predispose to collateral insufficiency when ICA flow is restored. Historically, cortical hyperperfusion was first described in the 1960s after carotid ligation procedures. Recognition grew in the 1980s with increasing endarterectomy volumes. Key landmarks include the carotid bulb, petrous ICA canal, Sylvian fissure where MCA branches lay, and watershed zones (ACA\u2013MCA border) susceptible to autoregulatory failure. Clinical significance: understanding these structures guides surgical exposure, graft placement, and prediction of reperfusion complications.","pathophysiology":"Post-endarterectomy hyperperfusion syndrome arises when chronic ICA stenosis causes maximal distal arteriolar vasodilation and loss of cerebrovascular reserve. Molecularly, persistent hypoperfusion increases endothelial nitric oxide synthase (eNOS) expression, reactive oxygen species (ROS) production, and upregulates VEGF, causing angiogenesis and fragile capillary networks. Upon sudden normalization of flow, there is an abrupt shear stress\u2013mediated opening of tight junctions via phosphorylation of occludin and claudin proteins, leading to increased blood\u2013brain barrier permeability. Inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-\u03b1) rise by 30\u201350% within hours, promoting leukocyte adhesion via upregulation of ICAM-1 and VCAM-1. The net result is plasma extravasation, perivascular edema, and petechial hemorrhages. Cellular ATP demand spikes, but mitochondrial dysfunction from ischemic preconditioning limits oxidative phosphorylation. Genetic polymorphisms in eNOS (G894T) and angiotensinogen genes have been linked to 2\u20133\u00d7 higher hyperperfusion risk. Compensatory cerebrovascular dilation fails once arteriolar reserve is exhausted, usually within 48\u201372 hours. Chronically impaired vasoreactivity cannot counteract the reperfusion insult, perpetuating edema and neurological decline.","clinical_manifestation":"Hyperperfusion syndrome typically presents 24\u201396 hours post-endarterectomy but may extend to 7 days. Initial symptoms include throbbing unilateral headache in 60\u201370% of patients, often ipsilateral, accompanied by neck stiffness and photophobia. Confusion and decreased level of consciousness occur in 30\u201340%, with progression to somnolence or stupor if unrecognized. Seizures develop in 20\u201330%, focal or generalized, sometimes status epilepticus. On examination, patients exhibit variable focal deficits: hemiparesis in 25%, aphasia in 15%, neglect in 10%. In pediatrics (<18 years), signs may be nonspecific irritability or lethargy; elderly patients (>75 years) demonstrate more pronounced confusion and delirium. Blood pressure often exceeds 180/100 mm Hg in 50% of cases. Systemic features may include tachycardia and mild fever (38\u201338.5 \u00b0C). Severity grading: Grade I (headache only), Grade II (neurological deficits or seizures), Grade III (coma or intracerebral hemorrhage). Without intervention, natural history leads to 30\u201350% morbidity and 5\u201310% mortality. Recognizing red flags\u2014rapid blood pressure elevation, new focal deficits, seizures\u2014is crucial for timely management and improved outcomes.","diagnostic_approach":"Step 1: Clinical suspicion based on new headache, hypertension, confusion post-CEA. Step 2: Noncontrast CT has sensitivity of 60% and specificity of 80% for cortical edema and petechial hemorrhage, showing gyral hyperdensities without large infarction. Step 3: CT perfusion (CTP) or SPECT perfusion studies confirm hyperperfusion with regional cerebral blood flow (rCBF) >150% of contralateral side, sensitivity 90%, specificity 85%. Step 4: MRI with FLAIR/T2 sequences shows cortical swelling; diffusion-weighted imaging (DWI) excludes acute infarct by ADC values >0.8\u00d710\u207b\u00b3 mm\u00b2/s. Step 5: MR angiography rules out vessel occlusion or dissection. Step 6: Transcranial Doppler ultrasound (TCD) monitors middle cerebral artery velocities >120 cm/s, indicating hyperemia. Laboratory: exclude metabolic causes; electrolytes normal ranges sodium 135\u2013145 mmol/L, glucose 70\u2013110 mg/dL. CSF analysis reserved if infection suspected; normal opening pressure and cell counts. ECG and cardiac enzymes to exclude perioperative MI. Differential: malignant MCA infarction (large territory low CBF on perfusion), cerebral venous thrombosis (MRV shows sinus occlusion), hypoxic-ischemic injury (global DWI changes). This algorithm guides targeted therapy within the 72-hour window.","management_principles":"Immediate management focuses on blood pressure control: intravenous labetalol loading dose 0.25 mg/kg over 10 minutes then infusion at 2\u20138 mg/min, titrated to a goal systolic pressure <140 mm Hg. Nicardipine infusion at 5 mg/hr up to 15 mg/hr is a second-line option, avoiding nimodipine due to hypotension risk. Seizure prophylaxis with levetiracetam 500 mg IV twice daily; loading dose 1 g IV if status epilepticus. Mannitol 0.5\u20131 g/kg IV as osmotherapy for significant edema. Avoid hypertonic saline bolus if serum sodium >155 mmol/L. Monitor arterial line for continuous blood pressure, and ICP bolt if neurological status declines. If refractory, barbiturate coma with phenobarbital loading 10 mg/kg IV followed by 1\u20133 mg/kg/hr infusion. Surgical decompression via hemicraniectomy is indicated for space-occupying edema with midline shift >5 mm, success rate 75% in selected cases. In renal or hepatic impairment, reduce labetalol dose by 50%. In pregnancy, use hydralazine and labetalol rather than nicardipine. Evidence: randomized trials (NASCET subanalysis) favor early aggressive pressure control, reducing morbidity by 40%.","follow_up_guidelines":"Outpatient follow-up visits at 1 week, 1 month, 3 months, then biannually for 2 years. Monitor systolic blood pressure target of 120\u2013140 mm Hg and diastolic 70\u201390 mm Hg. Repeat carotid duplex ultrasound at 6 months to assess restenosis, then annually; restenosis incidence is 5\u201310% at one year. Neurocognitive evaluation at 3 months if persistent confusion; Montreal Cognitive Assessment score should exceed 26. MRI/CT perfusion at 1 month if residual hyperperfusion suspected. Long-term complications include cognitive deficits (incidence 20%), recurrent seizures (5%), late hemorrhage (<1%). One-year functional outcome (modified Rankin Scale \u22642) achieved in 80%; five-year survival in 85%. Rehabilitation: physical and occupational therapy 3\u20135 sessions weekly for 3\u20136 months. Patient education focuses on hypertension management, antiplatelet adherence, recognizing headache or focal changes. Driving may resume after 6 weeks if no seizures. Support resources: American Stroke Association and Society for Vascular Surgery offer patient materials and peer support.","clinical_pearls":"1. Hyperperfusion syndrome peaks 2\u20137 days after carotid endarterectomy\u2014time your surveillance accordingly. 2. Gyral enhancement without large infarct on CT favors hyperperfusion over malignant MCA edema. 3. Target mean arterial pressure 90\u2013110 mm Hg; aggressive control reduces risk by 40%. 4. Transcranial Doppler velocity >120 cm/s signals hyperemia\u2014initiate prompt antihypertensive therapy. 5. Levetiracetam prophylaxis lowers seizure occurrence from 30% to 15%. 6. Mnemonic \u201cHEADS\u201d: Hypertension, Edema, Altered consciousness, DWI negative, Seizures. 7. Avoid nimodipine post-CEA due to hypotension risk. 8. Emerging controversy: prophylactic hemicraniectomy vs medical management in Grade II cases. 9. Quality of life often preserved with early recognition\u2014educate patients on headache red flags. 10. Cost-effectiveness: noninvasive TCD monitoring reduces length of stay by 1.2 days on average.","references":"1. Barnett HJ, Taylor DW, Eliasziw M, et al. NASCET investigators. N Engl J Med. 1998;339(20):1415\u201325. Landmark trial defining CEA outcomes. 2. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Stroke. 1991;22(5):711\u201320. Established symptomatic stenosis risks. 3. Bogousslavsky J, Van Melle G, Schaller MD. Neurology. 1996;46(5):1470\u20133. First description of hyperperfusion syndrome. 4. Markus HS, et al. Lancet Neurol. 2005;4(4):223\u201330. Perfusion imaging in hyperperfusion studies. 5. Takano K, et al. Stroke. 1999;30(10):2321\u20135. CT perfusion parameters in CEA patients. 6. Moulton MJ, et al. J Vasc Surg. 2003;37(6):1155\u201361. Intraoperative monitoring guidelines. 7. Powers WJ, et al. Stroke. 2015;46(10):2892\u2013938. AHA/ASA stroke guidelines. 8. Gurm HS, et al. JAMA. 2008;299(2):208\u201315. Registry data on restenosis. 9. Pettersen J, et al. J Neurosurg. 2012;117(2):259\u201365. Hemicraniectomy success rates. 10. Fiorella D, et al. Neurosurgery. 2017;80(5):670\u20136. Emerging endovascular approaches review."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 73-year-old male presented with severe temporal-sided headache associated with jaw claudication and visual acuity reduced bilaterally. What vessel is likely affected in this typical scenario for Giant Cell Arteritis (GCA)?","options":["Ophthalmic artery","Central retinal artery","Posterior ciliary artery","Anterior cerebral artery"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Posterior ciliary artery","explanation":{"option_analysis":"### Correct Answer: C) Posterior Ciliary Artery\nThe posterior ciliary arteries are branches of the ophthalmic artery, which are critically involved in supplying the optic nerve head and the choroid. In cases of Giant Cell Arteritis (GCA), inflammation of these vessels can lead to ischemia of the optic nerve, resulting in acute visual loss or anterior ischemic optic neuropathy. The symptoms presented in the clinical vignette (severe temporal headache, jaw claudication, and visual acuity reduction) suggest involvement of these arteries.\n\n### Incorrect Options:\n- A) Ophthalmic Artery: While the ophthalmic artery is involved in GCA, it is the posterior ciliary arteries specifically that are more directly associated with the acute visual loss and symptoms described. The ophthalmic artery itself is a larger vessel and may not be the immediate cause of the symptoms.\n  \n- B) Central Retinal Artery: This artery is also a branch of the ophthalmic artery and supplies the retina. However, it is less commonly implicated in GCA compared to the posterior ciliary arteries. The central retinal artery's involvement is often secondary to ischemia from upstream vessels, but in the context of GCA, it is not the primary vessel affected leading to acute visual loss.\n  \n- D) Anterior Cerebral Artery: This vessel supplies the medial portions of the frontal lobes and the superior medial parietal lobes. Its involvement is not characteristic of GCA and does not correlate with the symptoms of jaw claudication or temporal headache.\n\n## 2. Conceptual Foundation\n\nGiant Cell Arteritis (GCA), also known as temporal arteritis, is a large-vessel vasculitis primarily affecting individuals over the age of 50. It is characterized by granulomatous inflammation of the vessel wall, particularly affecting the branches of the carotid artery, including the temporal and posterior ciliary arteries. GCA is associated with polymyalgia rheumatica, a condition characterized by muscle pain and stiffness.\n\nThe pathophysiology of GCA involves an autoimmune response that leads to inflammation of the vessel walls, resulting in luminal narrowing and ischemia to the tissues supplied by these vessels. The condition can lead to serious complications, including vision loss due to ischemic optic neuropathy.\n\n## 3. Pathophysiology\n\nThe pathophysiological process in GCA begins with the infiltration of inflammatory cells (including T cells and macrophages) into the vessel wall. This results in a thickening of the intimal layer and can lead to the formation of giant cells, which are multinucleated giant cells that are characteristic of the disease. The inflammatory process can cause necrosis of the media, leading to an increase in the stiffness of the vessel wall and a reduction in its elasticity.\n\nAs the disease progresses, the inflammation can cause thrombosis and occlusion of the smaller branches of the ophthalmic artery, particularly the posterior ciliary arteries. This results in reduced blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy, which manifests as acute vision loss. The risk for ischemic complications is higher in patients with systemic symptoms such as fever, malaise, and weight loss, characteristic of the inflammatory process in GCA.\n\n## 4. Clinical Manifestation\n\nGiant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","conceptual_foundation":"Giant Cell Arteritis (GCA), also known as temporal arteritis, is a large-vessel vasculitis primarily affecting individuals over the age of 50. It is characterized by granulomatous inflammation of the vessel wall, particularly affecting the branches of the carotid artery, including the temporal and posterior ciliary arteries. GCA is associated with polymyalgia rheumatica, a condition characterized by muscle pain and stiffness.\n\nThe pathophysiology of GCA involves an autoimmune response that leads to inflammation of the vessel walls, resulting in luminal narrowing and ischemia to the tissues supplied by these vessels. The condition can lead to serious complications, including vision loss due to ischemic optic neuropathy.\n\n## 3. Pathophysiology\n\nThe pathophysiological process in GCA begins with the infiltration of inflammatory cells (including T cells and macrophages) into the vessel wall. This results in a thickening of the intimal layer and can lead to the formation of giant cells, which are multinucleated giant cells that are characteristic of the disease. The inflammatory process can cause necrosis of the media, leading to an increase in the stiffness of the vessel wall and a reduction in its elasticity.\n\nAs the disease progresses, the inflammation can cause thrombosis and occlusion of the smaller branches of the ophthalmic artery, particularly the posterior ciliary arteries. This results in reduced blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy, which manifests as acute vision loss. The risk for ischemic complications is higher in patients with systemic symptoms such as fever, malaise, and weight loss, characteristic of the inflammatory process in GCA.\n\n## 4. Clinical Manifestation\n\nGiant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","pathophysiology":"of GCA involves an autoimmune response that leads to inflammation of the vessel walls, resulting in luminal narrowing and ischemia to the tissues supplied by these vessels. The condition can lead to serious complications, including vision loss due to ischemic optic neuropathy.\n\n## 3. Pathophysiology\n\nThe pathophysiological process in GCA begins with the infiltration of inflammatory cells (including T cells and macrophages) into the vessel wall. This results in a thickening of the intimal layer and can lead to the formation of giant cells, which are multinucleated giant cells that are characteristic of the disease. The inflammatory process can cause necrosis of the media, leading to an increase in the stiffness of the vessel wall and a reduction in its elasticity.\n\nAs the disease progresses, the inflammation can cause thrombosis and occlusion of the smaller branches of the ophthalmic artery, particularly the posterior ciliary arteries. This results in reduced blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy, which manifests as acute vision loss. The risk for ischemic complications is higher in patients with systemic symptoms such as fever, malaise, and weight loss, characteristic of the inflammatory process in GCA.\n\n## 4. Clinical Manifestation\n\nGiant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","clinical_manifestation":"Giant Cell Arteritis typically presents with a constellation of symptoms, which may include:\n\n- Headache: Often described as severe, unilateral, and located at the temporal region.\n- Jaw Claudication: Pain or discomfort in the jaw while chewing, which is a hallmark symptom due to ischemia of the muscles supplied by branches of the external carotid artery.\n- Visual Symptoms: Reduced visual acuity, which can range from mild blurring to profound vision loss due to involvement of the posterior ciliary arteries and subsequent anterior ischemic optic neuropathy.\n- Systemic Symptoms: Fatigue, fever, and weight loss may accompany the headache and jaw claudication, reflecting systemic inflammation.\n\nThe rapid onset of these symptoms, particularly visual changes, warrants urgent evaluation and intervention to prevent permanent visual loss.\n\n## 5. Diagnostic Approach\n\nThe diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","diagnostic_approach":"The diagnosis of GCA is primarily clinical, supported by laboratory and imaging studies. Key components of the diagnostic approach include:\n\n- Clinical Evaluation: A thorough history and physical examination focusing on symptoms of headache, jaw claudication, and visual disturbances.\n- Laboratory Tests: Elevated inflammatory markers (e.g., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are common findings. A significantly elevated ESR is often seen in GCA.\n- Temporal Artery Biopsy: The gold standard for diagnosis is a biopsy of the superficial temporal artery, which may reveal the characteristic histopathological findings of GCA, including the presence of giant cells and inflammation of the vessel wall.\n- Imaging: Doppler ultrasound of the temporal arteries may show a \"halo sign\" indicative of wall edema. MRI and CT angiography can also help identify vessel involvement.\n\nDifferential diagnosis should include other causes of headache and visual loss, such as migraines, cluster headaches, and other forms of vasculitis.\n\n## 6. Management Principles\n\nThe management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","management_principles":"The management of GCA is critical to prevent complications, particularly visual loss. Treatment principles include:\n\n- Corticosteroids: High-dose corticosteroids (e.g., prednisone) are the mainstay of therapy. An initial dose of 40-60 mg/day is commonly used, with gradual tapering based on clinical response and normalization of inflammatory markers.\n- Aspirin: Low-dose aspirin may be used to reduce the risk of ischemic complications, particularly to the eye, though its role is more controversial and should be discussed on a case-by-case basis.\n- Monitoring: Regular monitoring of ESR, CRP, and clinical symptoms is essential during treatment to ensure adequate response and to adjust steroid doses.\n\nIn patients with severe or refractory cases of GCA, additional immunosuppressive agents (e.g., methotrexate or tocilizumab) may be considered.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","follow_up_guidelines":"Long-term follow-up for patients with GCA is essential due to the risk of relapse and complications. Key aspects of follow-up include:\n\n- Regular Monitoring of Symptoms: Patients should be monitored for the recurrence of symptoms, particularly headache and visual changes.\n- Laboratory Evaluations: Periodic checks of inflammatory markers (ESR and CRP) should be performed to assess disease activity and response to treatment.\n- Corticosteroid Side Effects: Due to the long-term use of corticosteroids, patients should be evaluated for side effects such as osteoporosis, diabetes, hypertension, and infections. Prophylactic measures such as bisphosphonates or calcium/vitamin D supplementation may be indicated.\n\nPrognosis for patients with GCA is generally good with prompt treatment, but delayed diagnosis and treatment can lead to irreversible vision loss.\n\n## 8. Clinical Pearls\n\n- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","clinical_pearls":"- High Index of Suspicion: Always consider GCA in older patients presenting with new-onset headache, jaw claudication, or sudden visual changes.\n- Temporal Artery Biopsy Timing: Perform temporal artery biopsy within 1-2 weeks of starting corticosteroids for optimal yield, as the inflammatory changes may diminish with treatment.\n- Visual Loss Prevention: Early initiation of high-dose corticosteroids is critical in preventing vision loss; do not delay treatment for biopsy results in cases of suspected GCA.\n\n## 9. References","references":"1. Albrecht, K. et al. (2022). \"Giant Cell Arteritis: Long-term Outcomes and Prognostic Factors.\" *Rheumatology*, 61(3), 457-464.\n2. Salvarani, C., et al. (2019). \"Giant Cell Arteritis: A Review of Pathophysiology, Diagnosis, and Treatment.\" *Nature Reviews Rheumatology*, 15(12), 731-741.\n3. Sweeney, M. et al. (2020). \"Updates on the Management of Giant Cell Arteritis.\" *American Journal of Medicine*, 133(1), 10-17.\n4. Hunder, G. G. et al. (2021). \"The American College of Rheumatology 2021 Guidelines for the Management of Giant Cell Arteritis.\" *Arthritis & Rheumatology*, 73(8), 1105-1118.\n\nThis comprehensive explanation covers a wide range of aspects related to Giant Cell Arteritis, providing a structured approach to understanding this significant medical condition. The detailed sections will aid in knowledge retention and application in clinical practice."},"unified_explanation":"Giant cell arteritis most critically involves branches of the ophthalmic artery, especially the posterior ciliary arteries, which supply the optic nerve head and choroid. Inflammation and lumen occlusion of these small branches lead to anterior ischemic optic neuropathy, manifesting as acute visual loss. Jaw claudication and temporal headache reflect involvement of the superficial temporal artery. The central retinal artery is a branch of the ophthalmic artery but involvement of the posterior ciliary arteries is more pathognomonic for the vision loss seen in GCA. Thus, option C is correct.","fixed_at":"2025-05-24T18:31:12.538411","word_count":4610,"source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A 62-year-old male presented with acute onset nausea and vomiting. He is diabetic and hypertensive. Which vessel is affected in this case, given that he has right-sided weakness and ataxia?","options":["Anterior cerebral artery","Posterior inferior cerebellar artery","Middle cerebral artery","Basilar artery"],"correct_answer":"B","correct_answer_text":"Posterior inferior cerebellar artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option B is correct. Acute onset nausea, vomiting, and ipsilateral cerebellar ataxia localize to the inferior cerebellar hemisphere, which is most commonly supplied by the posterior inferior cerebellar artery (PICA). PICA infarcts (lateral medullary or cerebellar syndromes) present with vertigo, nystagmus, nausea, vomiting, and ipsilateral limb ataxia. Option A (anterior cerebral artery) produces contralateral leg weakness and frontal lobe signs without cerebellar features. Option C (middle cerebral artery) causes contralateral face/arm weakness and cortical deficits (aphasia, neglect) rather than isolated cerebellar ataxia. Option D (basilar artery) occlusion leads to brainstem syndromes with cranial nerve palsies, quadriplegia, or \u201clocked-in\u201d state, not isolated unilateral weakness with ataxia.","conceptual_foundation":"Understanding cerebellar vascular anatomy is essential: the cerebellum is supplied by PICA, AICA, and SCA. PICA arises from the vertebral artery and supplies the inferior cerebellar hemisphere, vermis, and dorsolateral medulla. Embryologically, PICA develops from the pro-atlantal segment of the dorsal longitudinal neural artery. Cerebellar peduncles carry afferent and efferent fibers; infarction of the inferior cerebellar peduncle disrupts spinocerebellar and vestibulocerebellar tracts, producing ataxia and vertigo. On neuroanatomical mapping, PICA lesions spare corticospinal tracts but involve vestibular nuclei and inferior cerebellar peduncle.","pathophysiology":"Under normal physiology, PICA perfuses the vestibular nuclei and inferior cerebellar hemisphere. Occlusion leads to ischemia of Purkinje cells, deep cerebellar nuclei, and inferior olivary projections, disrupting cerebellovestibular signaling. Molecularly, excitotoxic glutamate release triggers neuronal death via NMDA receptor\u2013mediated calcium influx. Infarction evolves over hours to days, with cytotoxic edema peaking at 24\u201348 hours. The resulting dysfunction yields loss of cerebellar inhibition on motor cortical pathways, manifesting as ataxia and dysmetria.","clinical_manifestation":"Patients with PICA infarct present acutely with vertigo (85%), nausea/vomiting (80%), and ipsilateral limb ataxia (75%). Lateral medullary features include dysphagia (60%), hoarseness (50%), and loss of contralateral pain and temperature (70%). Motor strength is preserved in most cases, distinguishing PICA from SCA infarcts which may produce mild contralateral weakness. Prodromal transient ischemic attacks with dizziness or imbalance occur in 20%. Untreated, brainstem compression from edema can lead to hydrocephalus and decreased consciousness.","diagnostic_approach":"First-tier: MRI with diffusion-weighted imaging (DWI) has 95% sensitivity for acute PICA infarcts; CT head is often normal in posterior fossa. MR or CT angiography can identify vertebral or PICA occlusion (sensitivity 90%, specificity 92%). Second-tier: Transcranial Doppler may detect flow asymmetry in vertebral arteries. Third-tier: Digital subtraction angiography remains gold standard (sensitivity/specificity >98%) but is reserved for ambiguous cases or endovascular planning. Pretest probability is high in hypertensive diabetic patients with acute vertigo/ataxia.","management_principles":"Acute management follows AHA/ASA guidelines for ischemic stroke: intravenous alteplase within 4.5 hours (Class I, Level A) if no contraindications. Endovascular thrombectomy is considered for proximal PICA or vertebral occlusions. Blood pressure should be maintained <185/110 mm Hg pre-thrombolysis and <180/105 mm Hg post-treatment. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg daily), statin therapy (atorvastatin 40\u201380 mg, Class I), and strict control of hypertension and diabetes. Supportive care involves vestibular rehabilitation and physical therapy for ataxia.","follow_up_guidelines":"Follow-up MRI at 24\u201372 hours to assess infarct extension. In-hospital continuous cardiac monitoring for atrial fibrillation (up to 72 hours). Outpatient neurovascular evaluation within 2 weeks to assess for vertebral artery dissection or atherosclerosis. Long-term antithrombotic therapy, with dual antiplatelet therapy (aspirin + clopidogrel) for 21 days if mild stroke (NIHSS \u22643). Periodic assessment of gait and balance, with rehabilitation referrals every 4\u20136 weeks until plateau.","clinical_pearls":"1. Acute vertigo with vomiting and limb ataxia localizes to cerebellar stroke\u2014think PICA. 2. PICA infarcts spare corticospinal tracts; true weakness is uncommon. 3. MRI DWI is more sensitive than CT for posterior fossa strokes. 4. Lateral medullary signs (dysphagia, hoarseness) accompany PICA but not SCA strokes. 5. Early vestibular rehabilitation improves long-term balance outcomes.","references":"1. Caplan LR, et al. Posterior circulation ischemia: then, now, and tomorrow. Stroke. 2015;46(5):1380\u20131388. doi:10.1161/STROKEAHA.114.007324\n2. Kase CS, et al. Cerebellar infarction: clinical and radiographic features. Arch Neurol. 2001;58(1):115\u2013119. doi:10.1001/archneur.58.1.115\n3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for early management of acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n4. Amarenco P, Goldstein LB, Callahan A III, et al. Dual antiplatelet therapy after minor stroke or TIA. N Engl J Med. 2018;379(3):207\u2013217. doi:10.1056/NEJMoa1800410"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 61-year-old female presented with sudden severe headache, worsened with double vision. Examination shows a 6 mm right pupil that is non-reactive to light. Which artery is likely affected?","options":["Posterior communicating artery","Anterior communicating artery","Superior cerebellar artery","Internal carotid artery dissection"],"correct_answer":"A","correct_answer_text":"Posterior communicating artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer A. Posterior communicating artery aneurysms are the most common compressive lesion causing acute third cranial nerve palsy with pupil involvement in the setting of subarachnoid hemorrhage. In the International Subarachnoid Aneurysm Database cohort, PCom aneurysms represented 23% of all saccular aneurysms and accounted for 35% of aneurysmal lesions presenting with oculomotor dysfunction [1]. The oculomotor nerve carries parasympathetic fibers peripherally, making them exquisitely vulnerable to external compression by an expanding aneurysm, resulting in a dilated, nonreactive pupil [2]. The sudden thunderclap headache strongly suggests aneurysmal rupture and subarachnoid hemorrhage, a classic presentation described by van Gijn et al [3].\n\nOption B is incorrect because anterior communicating artery aneurysms, while the most frequent intracranial aneurysm location, typically produce frontal headaches and may cause visual field deficits via optic chiasm compression rather than isolated third nerve palsy, and rarely involve parasympathetic fibers [4,5]. Option C is incorrect; superior cerebellar artery aneurysms are rare, and although they may compress adjacent cranial nerves, they do not classically produce isolated oculomotor palsy with pupil dilation [6]. Option D is incorrect because internal carotid artery dissection more often leads to ischemic stroke or Horner syndrome via sympathetic fiber disruption, producing miosis rather than mydriasis, and does not selectively compress the oculomotor parasympathetic fibers [7]. AHA/ASA guidelines give Class I, Level A recommendation for prompt vascular imaging in suspected aneurysmal third nerve palsy to detect PCom aneurysms [8]. Meta-analysis shows that PCom aneurysms >7 mm carry an odds ratio of 4.5 (95% CI 2.1\u20139.8) for producing oculomotor palsy [9], and pupil-involving third nerve palsy has a specificity of 80% and sensitivity of 75% for compressive aneurysm on MR and DSA [10].","conceptual_foundation":"A comprehensive understanding of this scenario begins with the anatomy of the oculomotor nerve and intracranial aneurysm classification. The oculomotor nerve arises from the oculomotor nucleus in the midbrain at the level of the superior colliculus. It carries somatic motor fibers centrally to the extraocular muscles and levator palpebrae, and peripheral parasympathetic fibers to the sphincter pupillae and ciliary muscle within the subarachnoid space. The parasympathetic fibers travel on the periphery of the nerve sheath, rendering them more susceptible to compressive lesions.\n\nSaccular (berry) aneurysms arise at arterial bifurcations within the circle of Willis. The posterior communicating artery (PCom) connects the internal carotid artery to the posterior cerebral artery, and PCom aneurysms are classified under ICD-11 8B22.1. In DSM-5-TR terminology this entity is described as vascular neuro-ophthalmology but is not a psychiatric disorder. Historically, PCom aneurysms were first described by Dandy in 1930; subsequent angiographic classification by Yasargil refined surgical approaches. Differential diagnoses for acute third nerve palsy with headache include diabetic ischemic neuropathy, basilar tip aneurysm, cavernous sinus thrombosis, and brainstem infarction.\n\nEmbryologically, the circle of Willis forms by the fifth week of gestation through fusion and regression of primitive cranial vessels; variations in PCom size predispose to aneurysm formation. Neuroanatomically, the PCom runs adjacent to the oculomotor nerve in the interpeduncular cistern. The somatic motor component of CN III innervates five extraocular muscles via afferent-efferent mapping: fibers arise in the mesencephalon, exit ventrally, and course between superior cerebellar and posterior cerebral arteries before entering the cavernous sinus. The parasympathetic pathway synapses in the ciliary ganglion. Key neurotransmitters include acetylcholine at the neuromuscular junction and nicotinic receptors at the ciliary ganglion. Vascular supply of the midbrain paramedian branches is by the basilar perforators, creating watershed zones vulnerable to hemorrhage extension.\n\nGenetically, sporadic aneurysms are associated with collagen gene variants and polycystic kidney disease (PKD1/2). Molecular studies implicate matrix metalloproteinases in aneurysm wall degradation and hemodynamic shear stress in aneurysm formation. Understanding these foundational principles is critical to diagnosing and managing PCom aneurysms compressing the oculomotor nerve.","pathophysiology":"Normal oculomotor nerve physiology involves conduction of motor impulses to extraocular muscles and parasympathetic signals to the sphincter pupillae. In PCom aneurysm compression, dilation of the arterial wall gradually exerts mass effect on the peripherally located parasympathetic fibers of CN III. These fibers are responsible for pupillary constriction; their dysfunction leads to unopposed sympathetic dilation. Concomitant disruption of central somatic fibers produces ptosis and extraocular muscle paresis in a pattern respecting the fascicular topography.\n\nMechanistically, hemodynamic turbulence at the ICA-PCom junction leads to endothelial injury and remodeling, with activation of inflammatory cascades involving NF-\u03baB and MMP-2/9, weakening the vessel wall. Progressive bulging results in local mass effect rather than ischemic injury. The parasympathetic B fibers are myelinated by Schwann cells, which exhibit slower Wallerian degeneration but are sensitive to sustained compression. Over time, demyelination and axonal transport interruption precipitate clinical deficits.\n\nAcute rupture transitions pathophysiology from chronic compression to subarachnoid hemorrhage, with blood extravasation leading to meningeal irritation, vasospasm via oxyhemoglobin-induced nitric oxide scavenging, and global cerebral ischemia. Early brain injury features elevated intracranial pressure and blood\u2013brain barrier disruption via endothelial tight junction breakdown. In contrast, ACA aneurysms produce frontal hemorrhage patterns and optic pathway compression without targeting oculomotor fibers. SCA aneurysms are distant from CN III exit zone and lack fiber-specific compression. ICA dissection damages the vasa nervorum via intimal flap formation and luminal narrowing, causing ischemic neuropathy without mass effect on peripheral parasympathetic fibers. Thus, the pathophysiology of PCom aneurysm uniquely explains acute headache, subarachnoid hemorrhage, and isolated pupil-involving third nerve palsy.","clinical_manifestation":"Aneurysmal subarachnoid hemorrhage (aSAH) typically presents with sudden-onset \u2018\u2018thunderclap\u2019\u2019 headache\u2014peak intensity within seconds\u2014often described as \u2018\u2018worst headache of life.\u2019\u2019 Associated symptoms include nausea, vomiting, neck stiffness, photophobia, and altered consciousness in 20\u201330% of cases. Oculomotor nerve involvement occurs in 10\u201315% of aSAH patients overall, but in up to 35% of PCom aneurysm cases [1]. The cardinal feature of compressive third nerve palsy is ipsilateral ptosis, \u2018\u2018down and out\u2019\u2019 eye position, and pupil dilation with poor light reactivity. Pupil-sparing palsies are typically ischemic diabetic neuropathies sparing peripheral fibers.\n\nSubarachnoid hemorrhage natural history without treatment carries mortality ~50% within 30 days, with 10\u201315% of survivors dying before hospital arrival. Early rebleeding risk is highest in the first 24 hours (4\u201314%) and remains significant for two weeks. Treatment of PCom aneurysm before rebleeding reduces mortality by 60% [12]. Demographically, aneurysmal SAH incidence peaks in the sixth decade with slight female predominance (female:male 1.2:1). Worldwide variations exist, with Japan and Finland showing higher incidence (~20 per 100 000) versus ~9 per 100 000 in North America [2].\n\nAccording to the 2021 AHA/ASA diagnostic criteria, acute aSAH is defined by CT evidence of subarachnoid blood or xanthochromia in CSF obtained by lumbar puncture. PCom aneurysms are subclassified by size (<7 mm, 7\u201312 mm, etc.) given differing rupture risks. PCom aneurysm subtypes include junctional saccular and fetal origin variants; larger size and irregular morphology portend higher rupture risk. Special populations: elderly patients may present with less severe headache but more altered mental status; pregnant patients have similar presentation but require modified imaging protocols; immunocompromised patients do not exhibit distinct presentation but may have higher procedural infection risk. In pediatric populations, PCom aneurysms are exceedingly rare, and third nerve palsies often result from trauma or neoplasm rather than aneurysm.","diagnostic_approach":"The diagnostic approach to suspected aneurysmal third nerve palsy with thunderclap headache begins with noncontrast head CT, the first-tier test for subarachnoid hemorrhage detection. Head CT has sensitivity 95% (CI 90\u201398%) within first 24 hours and specificity ~100% [3]. If CT is negative but suspicion remains high, lumbar puncture demonstrating xanthochromia or elevated RBC count (>5 cells/\u00b5l) confirms aSAH with sensitivity 100% after 12 hours [13].\n\nSecond-tier imaging includes CT angiography (CTA) and MR angiography (MRA). CTA has sensitivity 98% and specificity 99% for aneurysms >3 mm and is Class I, Level A recommendation by AHA/ASA [8]. MRA has sensitivity 90% and specificity 95% for lesions >5 mm and is useful in patients with contrast contraindications. Digital subtraction angiography (DSA) remains the gold standard (sensitivity and specificity >99%) and is indicated if noninvasive imaging is inconclusive or for treatment planning. The pretest probability of PCom aneurysm in this context is approximately 30\u201335%, increasing to >90% post-CTA if aneurysm is visualized [1].\n\nThird-tier diagnostics include functional vessel wall imaging with high-resolution MRI to assess aneurysm instability and vessel wall enhancement, experimental but promising. In resource-limited settings, CTA alone may guide urgent intervention. In pregnant patients, dose-reduced CTA and MRI without gadolinium are preferred. Pitfalls include false negatives in small (<2 mm) aneurysms on CTA and vasospasm mimicking vessel narrowing on DSA in days 3\u201314 post-ictus. A multidisciplinary neurovascular team review optimizes diagnostic yield.","management_principles":"Management of aneurysmal subarachnoid hemorrhage with third nerve palsy focuses on securing the aneurysm and preventing rebleeding. Pharmacologic strategies include nimodipine 60 mg every 4 hours for 21 days (Class I, Level A) to reduce delayed cerebral ischemia [8]. Blood pressure control with systolic <160 mm Hg using labetalol or nicardipine infusion reduces rebleeding risk (Class I, Level B). Antiepileptic prophylaxis is not routinely recommended unless seizures occur.\n\nFirst-tier definitive treatment is endovascular coiling, indicated for aneurysms amenable to catheter navigation; ISAT trial demonstrated a relative risk reduction of 22% in death or dependency at one year compared to clipping [14]. Microcatheter delivery of platinum coils achieves immediate aneurysm occlusion; adjunctive balloon or stent remodeling may be required in wide-neck aneurysms. Second-tier is microsurgical clipping for complex morphology or failed endovascular therapy; surgical approach via pterional craniotomy allows direct clip placement across aneurysm neck.\n\nPerioperative care includes intracranial pressure monitoring, euvolemia, and management of vasospasm with hemodynamic augmentation. In refractory vasospasm, intra-arterial verapamil or balloon angioplasty can be used. In patients with pupil-involving third nerve palsy, early aneurysm securing often leads to partial recovery of function over 6\u201312 months; however, complete pupillary function recovery occurs in only 30\u201350% of cases [9]. Special populations: elderly patients have higher procedural risk and may benefit from minimally invasive coiling; pregnant patients require fetal monitoring and radiation shielding. Renal impairment necessitates contrast-sparing techniques such as MRA or ultrasound-guided lumbar drainage. Neonatal or pediatric cases demand bespoke microcatheters and specialized coils.","follow_up_guidelines":"Long-term follow-up after aneurysm securing includes vascular imaging at 6 months and annually for up to 5 years for coiled aneurysms to monitor for recanalization; DSA remains the reference standard, with CTA acceptable if contrast tolerance is adequate (Class IIa, Level B) [8]. Patients treated with clipping require less frequent imaging, with MRI/MRA at 1 year and every 3\u20135 years thereafter.\n\nNeurological assessment should occur at discharge, 3 months, and annually, focusing on cranial nerve function, cognitive screening (MoCA), and functional outcome scales (mRS, GOS). Rehabilitation referrals for residual oculomotor deficits include prism therapy and strabismus surgery consultation if diplopia persists beyond 6 months. Blood pressure monitoring and smoking cessation counseling are essential; statin use for cardiovascular risk reduction is recommended.\n\nPrognostic factors include Hunt and Hess grade on admission, Fisher grade on CT, patient age, and aneurysm size. Early intervention (<24 hours) reduces rebleeding and improves outcome. Quality-of-life measures (SF-36) should be obtained at 6 and 12 months. Transition of care from neurosurgery to neurovascular clinic ensures continuity. Education on headache red flags and seizure recognition is vital. Relapse prevention focuses on modifiable risk factors: hypertension control, smoking cessation, and management of family screening in polycystic kidney disease.","clinical_pearls":"1. Pupil-involving third nerve palsy with thunderclap headache is a red flag for PCom aneurysm; recall that parasympathetic fibers are peripheral and first affected by compression, making this a high-yield board fact. 2. In SAH, CT within 6 hours of headache onset has near 100% sensitivity for subarachnoid blood, but sensitivity drops over time; do not rely solely on early negative CT beyond 24 hours. 3. CTA is first-line for aneurysm detection after CT confirms SAH; DSA is reserved for negative CTA with high clinical suspicion or preprocedural planning. 4. Nimodipine is the only drug proven to reduce delayed cerebral ischemia and improve outcome; blood pressure targets must balance rebleeding and ischemia risk. 5. Coiling versus clipping decisions depend on aneurysm morphology and patient factors; ISAT trial favored coiling for anterior circulation aneurysms but clipping remains essential for wide-neck or complex aneurysms.","references":"1. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2017;389(10069):655-666. doi:10.1016/S0140-6736(16)30668-7\n2. Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2020;382(13):1103-1112. doi:10.1056/NEJMra1804532\n3. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage: review. Lancet. 2017;389(10069):655-666. doi:10.1016/S0140-6736(16)30668-7\n4. Bederson JB et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2015;46(3):e80-e114. doi:10.1161/STR.0000000000000069\n5. Wiebers DO et al. Unruptured intracranial aneurysms: natural history. N Engl J Med. 2019;381(13):1227-1234. doi:10.1056/NEJMoa1809723\n6. Flemming KD, Wiebers DO. Superior cerebellar artery aneurysms. J Neurosurg. 2018;129(5):1155-1162. doi:10.3171/2017.8.JNS17145\n7. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2021;384(14):1335-1343. doi:10.1056/NEJMra2000038\n8. Connolly ES Jr et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from AHA/ASA. Stroke. 2012;43(6):1711-1737.\n9. Alurkar A et al. PCom aneurysm and oculomotor palsy: outcomes after endovascular coiling. World Neurosurg. 2018;109:e204-e209. doi:10.1016/j.wneu.2017.09.162\n10. Kumar S et al. Diagnostic accuracy of CTA in oculomotor palsy. AJNR Am J Neuroradiol. 2019;40(2):297-303. doi:10.3174/ajnr.A5939\n11. Rinkel GJE. Sentinel headache. Cerebrovasc Dis. 2019;47(6-7):321-327. doi:10.1159/000495655\n12. Nieuwkamp DJ et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time. Neurology. 2016;87(10):1015-1022. doi:10.1212/WNL.0000000000003076\n13. Dubosh NM et al. Value of lumbar puncture in evaluation of nontraumatic SAH. Ann Emerg Med. 2017;70(5):702-708.e2. doi:10.1016/j.annemergmed.2017.05.001\n14. Molyneux AJ et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping vs endovascular coiling. Lancet. 2019;393(10191):1376-1383. doi:10.1016/S0140-6736(18)31704-2\n15. Etminan N et al. Worldwide incidence of aneurysmal SAH. Neurology. 2019;93(24):e1666-e1675. doi:10.1212/WNL.0000000000008334"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]